Opicinumab: is it a potential treatment for multiple sclerosis?

Research output: Contribution to journalEditorialpeer-review

Colleges, School and Institutes


Cadavid et al. (1) reported the results of the SYNERGY trial using opicinumab, which is a fully humanised antiLINGO-1 antibody in multiple sclerosis (MS) patients.The study evaluated the clinical safety, efficacy, and pharmacokinetics of four different doses of opicinumab versus placebo added on to intramuscular interferon-β1a over 72 weeks in patients with relapsing MS. However, the findings of the clinical trial did not show a significant doselinear improvement in disability compared with placebo in patients with relapsing MS.


Original languageEnglish
JournalAnnals of Translational Medicine
Early online date5 Mar 2020
Publication statusE-pub ahead of print - 5 Mar 2020